CHEK2 and breast carcinoma: Narod's [48] recent review supports the view that testing non-BRCA HBC families for mutations in CHEK2 can provide useful information to evaluate the risk of breast cancer and suggests that the relatively high cost of sequencing makes only the targeted search of frequent mutations cost-effective.